Inhaled Antibiotics Market 2024 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2030
Page: 215 | Report Code: LS241004 | Research Suite: Report (PDF) & Market Data (Excel)
The global market value of the inhaled antibiotics market was valued at USD 1.2 billion in 2022, and a CAGR of 6.6% is anticipated during the forecast period. Increasing incidences of chronic respiratory disorders like asthma, COVID-19, and several other respiratory diseases are driving growth in the market significantly. Chronic conditions like cystic fibrosis, COPD, and bronchiectasis often require long-term management, including antibiotics to control infections.
Inhaled antibiotics target the lungs directly, leading to faster action and higher local concentration with fewer systematic side effects. Growing need for targeted therapies to minimize the overuse of systematic antibiotics and reduce antibiotic resistance. The global geriatric population is more susceptible to chronic lung diseases, and increasing demand for their treatment is driving growth in the market.
Growth Drivers
Ventilator associated Pneumonia and other lungs infections in hospital settings are prompting demand for more effective inhaled antibiotics. Developing inhaled formulations of antibiotics is expensive due to the need for specialized delivery systems. Innovations in drug delivery systems, such as nebulizers and dry powder inhalers, are expected to improve the efficacy. The increasing world population is inspiring for some advanced steps to be taken by government.
Growing concern over antibiotic resistance has led to the development of inhaled antibiotics as a way to provide a high concentration of the drug at the site of infection, reducing the overall dosage and minimizing the risk of assistance. With an aging world population, particularly in developed countries, the prevalence of respiratory diseases is increasing, leading to higher demand for inhaled antibiotics to manage infections in older adults.
A growing number of pharmaceutical companies are
investing in the development of novel inhaled antibiotics, expanding treatment
options for multidrug-resistant infections, and other difficult-to-treat respiratory
conditions. Shift towards outpatient care and home healthcare services,
particularly for patients with chronic conditions, is propelling the demand for
more convenient and effective inhaled antibiotic therapies.
Increasing elderly population and rising prevalence of lung
diseases are driving growth in the market significantly.
Segmentation
By Product Type
·
Aerosol/Metered Dose Inhaler
·
Dry Powder Formulation
·
Spray
·
Others
By Distribution Channel
·
Hospital Pharmacies
·
Retail Pharmacies
·
Online Pharmacies
By Application
·
Pneumonia
·
Asthma
·
Bronchitis
·
Others
Regional Outlook
·
Asia Pacific
·
North America
·
Latin America
·
Middle East and Africa
·
Europe
Inhaled Antibiotics Market by
Application Segmentation
On the basis of the application, the inhaled antibiotics market is segmented into pneumonia, asthma, bronchitis, and others. Pneumonia tends to be the leading segment in the market and is expected to dominate the market during the forecast period. Bacterial infections causing pneumonia are severe and require targeted antibiotic treatment to improve lung function and reduce bacterial load. Inhaled antibiotics are useful for delivering high concentrations directly to the lungs, improving efficacy.
Pneumonia affects a large number of patients worldwide, particularly the elderly and those with weakened immune systems, making it a significant driver of inhaled antibiotic use. In patients with chronic pneumonia, especially those with underlying conditions such as COPD, inhaled antibiotics help manage persistent bacterial infection. Inhaled antibiotics are also useful in cases of asthma. There is no treatment for asthma, but treatment like inhaler antibiotics is helpful in treating the symptoms like wheezing, chest tightness, and shortness of breath.
Exposure to tobacco smoke also makes a person asthma-prone. Increasing
awareness all over the world about the rising lung diseases is driving growth
in the market. The COVID-19 pandemic was also a chronic disease that usually
affected the lungs. Post-pandemic people were more careful about the diseases
affecting the lungs.
The increasing elderly population and rising prevalence of
lung diseases are driving growth in the market significantly.
Inhaled Antibiotics Market by
Distribution Channel Segmentation
On the basis of the distribution channel, the inhaled antibiotics market is segmented into hospitals, retail pharmacies, and online pharmacies. Retail pharmacies are the leading segment in the market due to the ease of availability of products on Retain stores. Online pharmacies are expected to dominate the market significantly during the forecast period.
The
increasing number of retail pharmacies in emerging economies is driving growth
in the market. Growing concern over antibiotic resistance has led to the
development of inhaled antibiotics as a way to provide a high concentration of
the drug at the site of infection, reducing the overall dosage and minimizing
the risk of assistance. Rising healthcare expenditure and increasing awareness
among the people about lung diseases are driving growth in the market.
The increasing elderly population and rising prevalence of
lung diseases are driving growth in the market significantly.
Regional Outlook
On the basis of the regions, the inhaled antibiotic market is segmented into 5 regions: Asia Pacific, North America, Europe, the Middle East and Africa, and Latin America. Asia Pacific is the leading segment due to the rapidly increasing geriatric population and rising healthcare expenditure. Increasing urbanization is the key cause behind the significant growth in the market. An increasing number of patients with cystic fibrosis and chronic obstructive pulmonary diseases is driving growth in the United States of America. The region has an advanced healthcare system with better access to novel treatments, higher spending capacity, and more established reimbursement policies.
The U.S. is home to many leading pharmaceutical companies, research institutions, and regulatory bodies, like the FDA, which promotes innovation and approves new inhaled antibiotics. Greater awareness and early diagnosis of respiratory diseases are the key factors behind the significant growth in the market. Rising disposable income in the region is the main cause behind the significant growth. Countries like China and India, which are emerging economies, are witnessing significant growth in the market. The United States of America and Canada are expected to dominate the market during the forecast period due to well-established healthcare infrastructure. Increasing health awareness among the people of the North American region is the main reason behind the significant growth in the market.
The rising number of chronic disease patients and the
increasing number of geriatric people in the European region are driving growth
significantly in the market. The increasing number of asthma patients all over
the world is driving growth in the market significantly. The presence of major
key players in Asia Pacific and North America is witnessing significant growth
in the market. The rising population of geriatric people all over the world is
a driving factor in the market significantly.
Key Players
·
Gilead Sciences
·
Aradigm
·
Lupid Ltd.
·
Polyphor
·
Insmed Incorporation
·
Savara Pharmaceuticals
·
Teva Canada Ltd.
·
Altan Pharmaceuticals
·
Pharmaxis Ltd.
· Other Players